The approval of durvalumab, based on data from the phase 3 ADRIATIC study, offers a new standard of care for patients with ...

Imfinzi was approved by the FDA for the treatment of adults with limited-stage small cell lung cancer without disease ...

it is recommended to complete the 2-week course of PCI well within this timeframe. Although early clinical trials of ICIs in patients with metastatic non–small cell lung cancer indicated the potential ...

The agency granted approval to durvalumab for the treatment of a subset of patients with limited-stage small cell lung cancer ...

Erratum: Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Single-Arm ... of concurrent chemoradiotherapy.

The U.S. Food and Drug Administration has approved AstraZeneca blockbuster drug Imfinzi to treat some adults with ...

An FDA-approved drug used to treat multiple myeloma and lymphoma also shrank tumors in non-small cell lung cancer (NSCLC) ...

The FDA has approved the drug durvalumab for adults with limited-stage small-cell lung cancer (LS-SCLC) whose disease hasn’t ...

The highly anticipated PROSPECT-Lung trial has officially opened, marking a significant step forward in the quest to improve treatment strategies for patients with resectable non-small cell lung ...

The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), as a single agent, for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has ...

The approval was supported by the randomized, double-blind, placebo-controlled phase 3 ADRIATIC study. Results showed durvalumab reduced the risk of death by 27% and disease progression or death ...